Novo Nordisk Enters a Pivotal Week as a Failed Trial, Legal Pressures, and Earnings Converge

Novo Nordisk faces Phase 3 failure, shareholder lawsuit, and Lilly dispute ahead of August 5 earnings; shares down 25% from high.

The Danish pharmaceutical giant is navigating one of its most turbulent stretches in recent memory, with a failed late-stage study, an active shareholder lawsuit, and a looming earnings report all colliding within days of one another. Novo Nordisk's shares closed Friday at EUR 40.90, down 8.48% on the day, leaving the stock 25.45% below its 52-week high of EUR 54.86 reached in January.

A Missed Endpoint That Shook the Sector

The immediate trigger for Friday's slide was the disclosure that Ziltivekimab, an anti-inflammatory candidate acquired through the $725 million takeover of Corvidia in 2020, had failed its Phase 3 ZEUS trial. The study, which enrolled more than 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammatory markers, showed the drug did reduce the biomarkers interleukin-6 and hsCRP as expected. However, the rate of major adverse cardiovascular events was not significantly lowered, with a hazard ratio of 0.99 and a confidence interval of 0.88 to 1.11. The drug also produced more serious infections than placebo, while overall mortality showed no difference.

The disappointment rippled beyond Novo Nordisk itself. Shares of other biotech companies with inflammation-focused programs fell as investors began questioning whether hsCRP reduction reliably predicts clinical benefit. Monte Rosa Therapeutics was hit hardest, dropping 27.5%, while BioAge Labs, Neurocrine, and Neumora also retreated.

Novo Nordisk's chief scientific officer, Martin Holst Lange, characterized the results as providing important scientific insights for ongoing research. Two related trials, HERMES and ARTEMIS, remain underway, with results expected in the first half of 2027. Management has stated that the 2026 profit outlook is unaffected by the setback, though a non-cash impairment charge will be recorded in the third quarter.

Legal Fronts Multiply

The ZEUS failure is not the only cloud hanging over the company. A US judge has allowed portions of a shareholder lawsuit to proceed, in which investors allege Novo Nordisk misled them about disappointing study results for the obesity drug CagriSema. The court found it plausible that certain statements about the drug's tolerability and the design of its late-stage trial could have been misleading, though the ruling stops well short of a fraud finding. A company spokesperson dismissed the allegations as unfounded and said Novo Nordisk would defend itself vigorously.

Adding to the legal entanglement, Novo Nordisk last week filed its own lawsuit against Eli Lilly, accusing the US rival of unfairly comparing its products in advertising to older, lower-dose Novo medications. Lilly has rejected the claim, pointing to available clinical evidence as the basis for its marketing.

The Numbers That Matter on August 5

Novo Nordisk will release first-half results on August 5, 2026, at 5:30 AM GMT, a date Reuters has flagged as one of the key events of the reporting season. The timing matters: figures published before the market opens are typically absorbed during the opening auction, whereas after-hours releases often delay the full price reaction until the following session.

Investors will be scrutinizing several areas. Sales and profit trends across the obesity and diabetes care segments will be central, as will any revision to the full-year guidance, particularly after management previously warned of pricing and competitive pressures. The commercial trajectory of the oral GLP-1 pill is also in focus, alongside how Wegovy and Ozempic are holding up against intensifying competition. Comments on the regulatory timeline for CagriSema will be closely watched, with a US Food and Drug Administration decision on the weight-management indication expected by the end of 2026.

A Valuation Question

Despite the sharp daily loss, the technical picture is more nuanced than the headline suggests. The stock remains about 1.35% above its 200-day moving average, indicating the longer-term trend has not fundamentally broken down. The relative strength index sits near 41.8, pointing to neither an oversold condition nor an imminent bounce.

Analysts at Jefferies and Citi viewed Friday's market reaction as exaggerated, though they acknowledged the strategic setback: Ziltivekimab was meant to help diversify Novo Nordisk beyond its diabetes and obesity franchise, a segment that reportedly accounts for roughly 94% of company revenue. Others note the equity now trades at a price-to-earnings ratio of around 11, close to multi-year lows, and argue that a still-expanding global GLP-1 market could make the current valuation attractive to patient investors.

The Wegovy tablet has reportedly launched successfully in the United States, the United Kingdom, and the United Arab Emirates, even as Eli Lilly's competitive pressure mounts. How Novo Nordisk navigates the intersection of trial disappointment, litigation, and its earnings call in the coming days will likely set the tone for the stock well into the third quarter.